Home > Uncategorized > AHA 2016: Some Heart Failure Presentations

AHA 2016: Some Heart Failure Presentations

  • EFFECT-HF: randomized clinical trial of patients with heart failure and iron deficiency comparing ferric carboxymaltose versus standard of care effect on exercise capacity. VO2 max improved.
  • IRONOUT: oral iron polysaccharide versus placebo in patients with heart failure with reduced ejection fraction. VO2 max primary end-point. Negative study.
  • REDUCELAPHF: 1 year outcome data of use of interatrial shunt device used in patients with heart failure and preserved ejection fraction and abnormal exercise pulmonary capillary wedge pressure (supine exercise). Symptomatic, exercise time, quality of life benefit and improved exercise capacity for given left atrial size.
  • ATHENA-HF: spironolactone (100 mg per day x 96 hours in acute heart failure) did not reduce NT proBNP compared with usual care
  • MOMENTUM-3: HEARTMATE 3 in advanced heart failure (compared to HEARTMATE II). The full paper is here
Advertisements
  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: